Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro

Muramyl dipeptide (MDP), eight new lipophilic MDP derivatives (MDPs) and three purified saponins were evaluated for their ability to induce immune responses in mice immunized with HIV-1 envelope protein rgp160 and for their ability to influence the HIV-1 replication in vitro. Three of nine new synth...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 15; no. 12; pp. 1479 - 1486
Main Authors: Krivorutchenko, Yuri L., Andronovskaja, Irina B., Hinkula, Jorma, Krivoshein, Yuri S., Ljungdahl-Ståhle, Ewa, Pertel, Sergey S., Grishkovets, Vladimir I., Zemlyakov, Alexander E., Wahren, Britta
Format: Journal Article
Language:English
Published: Oxford Elsevier Ltd 01-08-1997
Elsevier
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Muramyl dipeptide (MDP), eight new lipophilic MDP derivatives (MDPs) and three purified saponins were evaluated for their ability to induce immune responses in mice immunized with HIV-1 envelope protein rgp160 and for their ability to influence the HIV-1 replication in vitro. Three of nine new synthetic MDP derivatives (β-butyl-MDP, MTPO-26 and β-cholesteryl-MDP) and one saponin (Taurosid I) have been shown to induce strong humoral immune responses to HIV-1 envelope glycoproteins rgp160 and rgp120. Three substances (β-butyl-MDP, MDP-cholyl and β-G27-MDP) induced high levels of T-cell stimulation to HIV-1 rgp160. β-butyl-MDP induced the strongest B- and T-cell responses to HIV-1 glycoproteins. Two substances (β-butyl-MDP and Taurosid I) did not induce an enhancement of HIV-1 replication in vitro and can be considered as promising adjuvants.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(97)00065-0